BeiGene Total Assets 2014-2024 | ONC

BeiGene total assets for the quarter ending September 30, 2024 were $5.831B, a 5.54% increase year-over-year.

  • BeiGene total assets for 2023 were $5.805B, a 9% decline from 2022.
  • BeiGene total assets for 2022 were $6.379B, a 25.26% decline from 2021.
  • BeiGene total assets for 2021 were $8.536B, a 52.4% increase from 2020.

BeiGene Total Assets 2014-2024 | ONC

  • BeiGene total assets for 2023 were $5.805B, a 9% decline from 2022.
  • BeiGene total assets for 2022 were $6.379B, a 25.26% decline from 2021.
  • BeiGene total assets for 2021 were $8.536B, a 52.4% increase from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$153.4B
Gilead Sciences (GILD)$121.1B
Bristol Myers Squibb (BMY)$119.6B
Vertex Pharmaceuticals (VRTX)$118.9B
CSL (CSLLY)$83.5B
Regeneron Pharmaceuticals (REGN)$74B
GSK (GSK)$73.1B
Argenex SE (ARGX)$39.8B
Alnylam Pharmaceuticals (ALNY)$35B
BioNTech SE (BNTX)$29.7B
Illumina (ILMN)$21.1B
Biogen (BIIB)$21B
Moderna (MRNA)$15.2B
Incyte (INCY)$14.3B
Insmed (INSM)$13.7B
Intra-Cellular Therapies (ITCI)$13.5B
Genmab (GNMSF)$13B
Genmab (GMAB)$13B
BioMarin Pharmaceutical (BMRN)$12.1B
Bio-Techne Corp (TECH)$11.7B
Vaxcyte (PCVX)$11B
Sarepta Therapeutics (SRPT)$10.9B
Swedish Orphan Biovitrum (BIOVF)$10.9B
Exact Sciences (EXAS)$10.4B
Bio-Rad Laboratories (BIO.B)$10B
QIAGEN (QGEN)$9.9B
Exelixis (EXEL)$9.5B
Repligen (RGEN)$9.3B
Roivant Sciences (ROIV)$8.1B
Ascendis Pharma (ASND)$7.9B